# Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

> **NCT00005841** · PHASE1 · TERMINATED · sponsor: **University of Southern California** · enrollment: 15 (actual)

## Conditions studied

- Intraocular Melanoma
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** MART-1 antigen
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** progenipoietin
- **BIOLOGICAL:** tyrosinase peptide

## Key facts

- **NCT ID:** NCT00005841
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-06
- **Primary completion:** 2000-12
- **Final completion:** 2002-10
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Toxicity/Side Effects
- **Last updated:** 2014-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005841, "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*